Gastroenterology strain I Ulcerative colitis
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
2.5-25B CFU/capsule
FUNCTIONALITY
IBD-UC – IBD – Ulcerative colitis – Adjunct to standard therapy
Scientific support
Human clinical trials
Floch, Martin H. “Probiotic therapy for ulcerative colitis.” Journal of clinical gastroenterology 44.4 (2010): 237-238.
Henker, J., S. Müller, M.W Laass, A. Schreiner, and J. Schulze. “Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.” Zeitschrift fuer Gastroenterologie 46.09 (2008): 874-875.
Kruis, W., E. Schütz, P. Fric, B. Fixa, G. Judmaier, and M. Stolte. “Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.” Alimentary pharmacology & therapeutics 11.5 (1997): 853-858.
Kruis, W., P. Frič, J. Pokrotnieks, M. Lukáš, B. Fixa, M. Kaščák, M.A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, and C. Wolff. “Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.” Gut 53.11 (2004): 1617-1623.
